Plain-English translation of NCT06566716 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Neoplasms research guide →This trial is testing a new blood test called the CleoDX Ovarian Adnexal Mass Score Test System, which measures five markers in your blood to help doctors determine whether an ovarian mass is likely to be cancer or benign before surgery. Early research shows this new test works better than the current standard blood test (CA125) at identifying cancer. The study will enroll 1,000 women to confirm the test's accuracy.
Right now, doctors cannot definitively tell if an ovarian mass is cancerous until after surgery. This new blood test aims to solve that problem by providing more accurate information before surgery, helping doctors make better decisions about your care and ensuring those with cancer receive appropriate specialist treatment.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would provide a blood sample before your scheduled ovarian surgery. The researchers will then compare the results of this new blood test to the findings from your surgery to see how well the test predicted whether your mass was cancerous or benign. You would be part of a group of 1,000 women helping to validate whether this new test is accurate and useful for future patients.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States